The Goldman Sachs Group Raises Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $195.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price target hoisted by The Goldman Sachs Group from $170.00 to $195.00 in a research note published on Tuesday, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

Other equities research analysts also recently issued research reports about the stock. Stifel Nicolaus assumed coverage on shares of Ascendis Pharma A/S in a research report on Friday, May 31st. They issued a buy rating and a $200.00 target price for the company. StockNews.com raised Ascendis Pharma A/S from a sell rating to a hold rating in a research report on Thursday, May 23rd. JPMorgan Chase & Co. lifted their price objective on shares of Ascendis Pharma A/S from $167.00 to $170.00 and gave the stock an overweight rating in a report on Friday, May 3rd. Cantor Fitzgerald reissued an overweight rating and set a $173.00 target price on shares of Ascendis Pharma A/S in a report on Wednesday, May 15th. Finally, Morgan Stanley raised their target price on Ascendis Pharma A/S from $116.00 to $140.00 and gave the company an equal weight rating in a research note on Thursday, May 16th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, Ascendis Pharma A/S currently has a consensus rating of Moderate Buy and an average target price of $184.64.

Ascendis Pharma A/S Trading Down 0.1 %

ASND stock opened at $139.50 on Tuesday. The firm has a 50 day simple moving average of $132.84 and a 200-day simple moving average of $139.03. The company has a market capitalization of $8.12 billion, a P/E ratio of -14.52 and a beta of 0.63. Ascendis Pharma A/S has a twelve month low of $85.29 and a twelve month high of $161.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ASND. Lighthouse Investment Partners LLC purchased a new stake in shares of Ascendis Pharma A/S in the 2nd quarter valued at approximately $2,762,000. Fred Alger Management LLC boosted its position in shares of Ascendis Pharma A/S by 65.0% in the second quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company’s stock worth $41,879,000 after buying an additional 120,952 shares during the period. First Light Asset Management LLC purchased a new position in shares of Ascendis Pharma A/S during the second quarter valued at $4,931,000. Marshall Wace LLP raised its position in Ascendis Pharma A/S by 20.8% during the second quarter. Marshall Wace LLP now owns 30,289 shares of the biotechnology company’s stock valued at $4,131,000 after buying an additional 5,205 shares during the period. Finally, Tri Locum Partners LP lifted its stake in Ascendis Pharma A/S by 102.1% in the 2nd quarter. Tri Locum Partners LP now owns 227,762 shares of the biotechnology company’s stock worth $31,062,000 after acquiring an additional 115,092 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.